Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of doravirine + islatravir versus bictegravir + emtricitabine + tenofovir alafenamide in treatment-naive HIV-1 infection
MOH_2023-02-09_012344Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doravirine and islatravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
doravirineislatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on MOH_2023-02-09_012344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-09_012344.